Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878

SAFETY DATA SHEET



AQUATOP VIRTA 38 - RAL 9001

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier Product name

: AQUATOP VIRTA 38 - RAL 9001

1.2 Relevant identified uses of the substance or mixture and uses advised againstProduct use: Paint.

1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091. e-mail address of person : Prod-safe@teknos.com responsible for this SDS

National contact

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

1.4 Emergency telephone number

National advisory body/Poison Cent

Telephone number: In an emergency, call 112

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS] Not classified.

The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended. See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements		
Signal word	:	No signal word.
Hazard statements	:	No known significant effects or critical hazards.
Precautionary statements		
Prevention	:	Not applicable.
Response	:	Not applicable.
Storage	:	Not applicable.
Disposal	:	Not applicable.
Supplemental label elements	:	Contains adipohydrazide and 1,2-benzisothiazol-3(2H)-one. May produce an allergic reaction. Safety data sheet available on request. Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	

2.3 Other hazards

Date of issue/Date of revision: 22/05/2025Date of previous issueAQUATOP VIRTA 38 - RAL 9001

SECTION 2: Hazards identification

 Product meets the criteria
 : This mixture does not contain any substances that are assessed to be a PBT or a vPvB according vPvB.

 to Regulation (EC) No.
 1907/2006, Annex XIII

Other hazards which do : None known. not result in classification

SECTION 3: Composition/information on ingredients

: Mixture				
Identifiers	%	Classification	Specific Conc. Limits, M-factors and ATEs	Туре
REACH #: 01-2119489379-17 EC: 236-675-5 CAS: 13463-67-7	≥10 - ≤25	Carc. 2, H351 (inhalation)	-	[1] [*]
REACH #: 01-2119475104-44 EC: 203-961-6 CAS: 112-34-5 Index: 603-096-00-8	≤3	Eye Irrit. 2, H319	-	[1] [2]
REACH #: 01-2119962900-36 EC: 213-999-5 CAS: 1071-93-8	<1	Skin Sens. 1, H317 Aquatic Chronic 2, H411	-	[1]
EC: 220-120-9 CAS: 2634-33-5 Index: 613-088-00-6	<0.036	Acute Tox. 4, H302 Acute Tox. 2, H330 Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 See Section 16 for the full text of the H statements declared	ATE [Oral] = 450 mg/kg ATE [Inhalation (dusts and mists)] = 0.21 mg/l Skin Sens. 1, H317: C $\ge 0.036\%$ M [Acute] = 1 M [Chronic] = 1	[1]
	Identifiers REACH #: 01-2119489379-17 EC: 236-675-5 CAS: 13463-67-7 REACH #: 01-2119475104-44 EC: 203-961-6 CAS: 112-34-5 Index: 603-096-00-8 REACH #: 01-2119962900-36 EC: 213-999-5 CAS: 1071-93-8 EC: 220-120-9 CAS: 2634-33-5	Identifiers%REACH #: 01-2119489379-17 EC: 236-675-5 CAS: 13463-67-7 $\geq 10 - \leq 25$ REACH #: 01-2119475104-44 EC: 203-961-6 CAS: 112-34-5 Index: 603-096-00-8 ≤ 3 REACH #: 01-2119962900-36 EC: 213-999-5 CAS: 1071-93-8 <1 REACH #: 01-2119962900-36 EC: 213-999-5 CAS: 1071-93-8 <1 EC: 220-120-9 CAS: 2634-33-5 <0.036	Identifiers%ClassificationREACH #: 01-2119489379-17 EC: 236-675-5 CAS: 13463-67-7 $\geq 10 - \leq 25$ Carc. 2, H351 (inhalation)REACH #: 01-2119475104-44 EC: 203-961-6 CAS: 112-34-5 Index: 603-096-00-8 ≤ 3 Eye Irrit. 2, H319REACH #: 01-2119962900-36 EC: 213-999-5 CAS: 1071-93-8 ≤ 1 Skin Sens. 1, H317 Aquatic Chronic 2, H411EC: 220-120-9 CAS: 2634-33-5 Index: 613-088-00-6 < 0.036 Acute Tox. 4, H302 Acute Tox. 2, H330 Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Chronic 1, H410See Section 16 for the full text of the H	$\begin{tabular}{ c c c c c c c } \hline Identifiers & \% & Classification & Specific Conc. Limits, M-factors and ATEs and AT$

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Туре

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter \leq 10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

Eye contact	 Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
Inhalation	: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
Skin contact	 Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.

Date of issue/Date of revision	: 22/05/2025	Date of previous issue	: No previous validation	Version	:1	2/21
AQUATOP VIRTA 38 - RAL 9001				Label No	1188	54

Ingestion Protection of first-aiders 4.2 Most important symptom <u>Over-exposure signs/sympt</u> Eye contact Inhalation Skin contact Ingestion	: sa : <u>: :</u>	No specific data.
2.2 Most important symptom <u>Over-exposure signs/sympt</u> Eye contact Inhalation Skin contact	sa :om :	nd effects, both acute and delayed IS No specific data.
Over-exposure signs/sympt Eye contact Inhalation Skin contact	<u>om</u> : :	No specific data.
Eye contact Inhalation Skin contact	:	No specific data.
Inhalation Skin contact	:	•
Skin contact		N La construction de la construc
	÷.,	No specific data.
Ingestion		No specific data.
	:	No specific data.
4.3 Indication of any immedia	ate	medical attention and special treatment needed
Notes to physician	:	Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
Specific treatments	:	No specific treatment.
SECTION 5: Firefight	in	g measures
5.1 Extinguishing media		
Suitable extinguishing media	:	Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	:	None known.
5.2 Special hazards arising fr	om	the substance or mixture
Hazards from the substance or mixture	:	In a fire or if heated, a pressure increase will occur and the container may burst.
Hazardous combustion products	:	Decomposition products may include the following materials: carbon dioxide carbon monoxide metal oxide/oxides
5.3 Advice for firefighters		
Special protective actions for fire-fighters	:	Promptly isolate the scene by removing all persons from the vicinity of the incident there is a fire. No action shall be taken involving any personal risk or without suitable training.
Special protective equipment for fire-fighters	:	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

6.1 Personal precautions, pro	ote	ctive equipment and emergency procedures
For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
For emergency responders	:	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
Date of issue/Date of revision		: 22/05/2025 Date of previous issue : No previous validation Version : 1 3/21

AQUATOP VIRTA 38 - RAL 9001

SECTION 6: Accidental release measures

6.3 Methods and material for containment and cleaning up

Small spill	: Stop leak if without risk. Move containers from spill area. Absorb with an inert material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	: Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contain and collect spillage with non-combustible, absorbent material e. g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.
6.4 Reference to other sections	: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8).
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)	
Recommendations	: Not available.
Industrial sector specific solutions	: Not available.

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

Product/ingredient name	Exposure limit values			
2-(2-butoxyethoxy)ethanol	Regulation on Limit Values - MAC (Austria, 4/2021) TWA 8 hours: 10 ppm. TWA 8 hours: 67.5 mg/m ³ . PEAK 15 minutes: 15 ppm 4 times per shift. PEAK 15 minutes: 101.2 mg/m ³ 4 times per shift.			
2-(2-butoxyethoxy)ethanol	Limit values (Belgium, 12/2023) STEL 15 minutes: 15 ppm. TWA 8 hours: 10 ppm. TWA 8 hours: 67.5 mg/m ³ . STEL 15 minutes: 101.2 mg/m ³ .			
Date of issue/Date of revision : 22/05/20 AQUATOP VIRTA 38 - RAL 9001	025 Date of previous issue : No previous validation Version : 1 4/21 Label No :118854			

2-(2-butoxyethoxy)ethanol	Ministry of Labour and Social Policy and the Ministry of Health - Ordinance No 13/2003. (Bulgaria, 4/2024) Limit value 8 hours: 67.5 mg/m ³ . Limit value 15 minutes: 101.2 mg/m ³ . Limit value 15 minutes: 15 ppm. Limit value 8 hours: 10 ppm.			
2-(2-butoxyethoxy)ethanol	Ordinance on the protection of workers from exposure to hazardous chemicals at work, exposure limit values (Anne (Croatia, 12/2023) STELV 15 minutes: 101.2 mg/m ³ . STELV 15 minutes: 15 ppm. ELV 8 hours: 67.5 mg/m ³ . ELV 8 hours: 10 ppm. Department of labour inspection (Cyprus, 7/2021) STEL 15 minutes: 15 ppm. STEL 15 minutes: 15 ppm. STEL 15 minutes: 101.2 mg/m ³ . TWA 8 hours: 10 ppm. TWA 8 hours: 67.5 mg/m ³ .			
2-(2-butoxyethoxy)ethanol				
e-(2-butoxyethoxy)ethanol	Government regulation of Czech Republic PEL/NPK-P (Czec Republic, 12/2023) TWA 8 hours: 67.5 mg/m ³ . TWA 8 hours: 10 ppm. STEL 15 minutes: 101.2 mg/m ³ . STEL 15 minutes: 15 ppm.			
2-(2-butoxyethoxy)ethanol	Working Environment Authority (Denmark, 3/2024) TWA 8 hours: 68 mg/m ³ . TWA 8 hours: 10 ppm. STEL 15 minutes: 15 ppm. STEL 15 minutes: 101 mg/m ³ .			
2-(2-butoxyethoxy)ethanol	Occupational exposure limits, Regulation No. 293 (Estonia, 4/2024) TWA 8 hours: 10 ppm. TWA 8 hours: 67.5 mg/m ³ .			
2-(2-butoxyethoxy)ethanol	EU OEL (Europe, 1/2022) TWA 8 hours: 67.5 mg/m ³ . TWA 8 hours: 10 ppm. STEL 15 minutes: 101.2 mg/m ³ . STEL 15 minutes: 15 ppm.			
?-(2-butoxyethoxy)ethanol	Institute of Occupational Health, Ministry of Social Affairs (Finland, 10/2021) TWA 8 hours: 10 ppm. TWA 8 hours: 68 mg/m ³ .			
?-(2-butoxyethoxy)ethanol	Ministry of Labor (France, 6/2024) STEL 15 minutes: 101.2 mg/m ³ . Notes: Indicative regulatory lim values (decree of 30-06-2004 modified) STEL 15 minutes: 15 ppm. Notes: Indicative regulatory limit values (decree of 30-06-2004 modified) TWA 8 hours: 67.5 mg/m ³ . Notes: Indicative regulatory limit values (decree of 30-06-2004 modified) TWA 8 hours: 10 ppm. Notes: Indicative regulatory limit values (decree of 30-06-2004 modified)			
2-(2-butoxyethoxy)ethanol	 TRGS 900 OEL (Germany, 6/2024) TWA 8 hours: 67 mg/m³. PEAK 15 minutes: 100.5 mg/m³. TWA 8 hours: 10 ppm. PEAK 15 minutes: 15 ppm. DFG MAC-values list (Germany, 7/2023) Develop C. TWA 8 hours: 67 mg/m³. PEAK 15 minutes: 100.5 mg/m³ 4 times per shift [Interval: 1 hour]. PEAK 15 minutes: 15 ppm 4 times per shift [Interval: 1 hour]. 			

1,2-benzisothiazol-3(2H)-one	DFG MAC-values list (Germany, 7/2023) Skin sensitiser.
2-(2-butoxyethoxy)ethanol	Presidential Decree 307/1986: Occupational exposure limit values (Greece, 9/2021) STEL 15 minutes: 101.2 mg/m ³ . STEL 15 minutes: 15 ppm. TWA 8 hours: 67.5 mg/m ³ . TWA 8 hours: 10 ppm.
2-(2-butoxyethoxy)ethanol	5/2020. (II. 6.) ITM Decree (Hungary, 12/2023) TWA 8 hours: 67.5 mg/m ³ . PEAK 15 minutes: 101.2 mg/m ³ . PEAK 15 minutes: 15 ppm. TWA 8 hours: 10 ppm.
2-(2-butoxyethoxy)ethanol	Ministry of Welfare, List of Exposure Limits (Iceland, 11/2023 STEL 15 minutes: 101.2 mg/m ³ . STEL 15 minutes: 15 ppm. TWA 8 hours: 67.5 mg/m ³ . TWA 8 hours: 10 ppm.
2-(2-butoxyethoxy)ethanol	 NAOSH (Ireland, 4/2024) Notes: EU derived Occupational Exposure Limit Values OELV 8 hours: 10 ppm. OELV 15 minutes: 101.2 mg/m³. OELV 8 hours: 67.5 mg/m³. OELV 15 minutes: 15 ppm.
2-(2-butoxyethoxy)ethanol	Legislative Decree No. 81/2008. Title IX. Protection from chemical agents, carcinogens and mutagens (Italy, 6/2020) Limit value 8 hours: 10 ppm. Limit value 8 hours: 67.5 mg/m ³ . Short Term 15 minutes: 15 ppm. Short Term 15 minutes: 101.2 mg/m ³ .
2-(2-butoxyethoxy)ethanol	Ministers Cabinet Regulations Nr.325 - AER (Latvia, 3/2024) STEL 15 minutes: 101.2 mg/m ³ . TWA 8 hours: 10 ppm. STEL 15 minutes: 15 ppm. TWA 8 hours: 67.5 mg/m ³ .
2-(2-butoxyethoxy)ethanol	Lithuanian Hygiene Standard HN 23 (Lithuania, 1/2024) TWA 8 hours: 67.5 mg/m ³ . TWA 8 hours: 10 ppm. STEL 15 minutes: 101.2 mg/m ³ . STEL 15 minutes: 15 ppm.
2-(2-butoxyethoxy)ethanol	Grand-Duchy Regulation 2016. Chemical agents. Annex I (Luxembourg, 3/2021) STEL 15 minutes: 15 ppm. STEL 15 minutes: 101.2 mg/m ³ . TWA 8 hours: 10 ppm. TWA 8 hours: 67.5 mg/m ³ .
2-(2-butoxyethoxy)ethanol	EU OEL (Europe, 1/2022) TWA 8 hours: 67.5 mg/m ³ . TWA 8 hours: 10 ppm. STEL 15 minutes: 101.2 mg/m ³ . STEL 15 minutes: 15 ppm.
2-(2-butoxyethoxy)ethanol	Ministry of Social Affairs and Employment, Legal limit values (Netherlands, 5/2024) Absorbed through skin. TWA 8 hours: 50 mg/m ³ . STEL 15 minutes: 100 mg/m ³ . TWA 8 hours: 7.4 ppm. STEL 15 minutes: 14.8 ppm.
2-(2-butoxyethoxy)ethanol	FOR-2011-12-06-1358 (Norway, 12/2022) TWA 8 hours: 10 ppm. TWA 8 hours: 68 mg/m ³ .

2-(2-butoxyethoxy)ethanol	Regulation of the Minister of Family, Labor and Social Policy of June 12, 2018 on the maximum permissible concentrations and intensities of factors harmful to health in the work environment (Journal of Laws of 2018, item 1286) (Poland, 8/2023) TWA 8 hours: 67 mg/m ³ . STEL 15 minutes: 100 mg/m ³ .
2-(2-butoxyethoxy)ethanol	Portuguese Institute of Quality (Portugal, 11/2014) TWA 8 hours: 10 ppm. Form: Inhalable fraction and vapor.
2-(2-butoxyethoxy)ethanol	HG 1218/2006, Annex 1, with subsequent modifications and additions (Romania, 3/2024) VLA 8 hours: 67.5 mg/m ³ . Short term 15 minutes: 101.2 mg/m ³ . Short term 15 minutes: 15 ppm. VLA 8 hours: 10 ppm.
2-(2-butoxyethoxy)ethanol	Government regulation SR c. 355/2006 (Slovakia, 7/2024) Inhalation sensitiser. TWA 8 hours: 67.5 mg/m ³ . STEL 15 minutes: 101.2 mg/m ³ . TWA 8 hours: 10 ppm. STEL 15 minutes: 15 ppm.
2-(2-butoxyethoxy)ethanol	Regulation on protection of workers from the risks related to exposure to chemical substances at work (Slovenia, 4/2024) TWA 8 hours: 67.5 mg/m ³ . TWA 8 hours: 10 ppm. KTV 15 minutes: 101.2 mg/m ³ 4 times per shift [time between two exposure events at this concentration must be at least 60 minutes]. KTV 15 minutes: 15 ppm 4 times per shift [time between two exposure events at this concentration must be at least 60 minutes].
2-(2-butoxyethoxy)ethanol	National institute of occupational safety and health (Spain, 1/2024) TWA 8 hours: 67.5 mg/m ³ . TWA 8 hours: 10 ppm. STEL 15 minutes: 15 ppm. STEL 15 minutes: 101.2 mg/m ³ .
2-(2-butoxyethoxy)ethanol	Work environment authority Regulation 2018:1 (Sweden, 11/2022) TWA 8 hours: 10 ppm. TWA 8 hours: 68 mg/m ³ . STEL 15 minutes: 15 ppm. STEL 15 minutes: 101 mg/m ³ .
2-(2-butoxyethoxy)ethanol	SUVA (Switzerland, 1/2024) TWA 8 hours: 67 mg/m ³ . Form: vapour and aerosols. STEL 15 minutes: 101 mg/m ³ . Form: vapour and aerosols. STEL 15 minutes: 15 ppm. Form: vapour and aerosols. TWA 8 hours: 10 ppm. Form: vapour and aerosols.
2-(2-butoxyethoxy)ethanol	EH40/2005 WELs (United Kingdom (UK), 1/2020) TWA 8 hours: 10 ppm. TWA 8 hours: 67.5 mg/m ³ . STEL 15 minutes: 15 ppm. STEL 15 minutes: 101.2 mg/m ³ .

Biological exposure indices

Product/ingredient	name	Exposure indices
No exposure indices known.		
· · · · · · · · · · · · · · · · · · ·		d he made to monitoring standards, such as the following:
Recommended monitoring procedures	European Stand assessment of e values and mea atmospheres - (of exposure to c (Workplace atm for the measure	Id be made to monitoring standards, such as the following: dard EN 689 (Workplace atmospheres - Guidance for the exposure by inhalation to chemical agents for comparison with limit isurement strategy) European Standard EN 14042 (Workplace Guide for the application and use of procedures for the assessment chemical and biological agents) European Standard EN 482 isospheres - General requirements for the performance of procedure ment of chemical agents) Reference to national guidance nethods for the determination of hazardous substances will also be
DNELs/DMELs	,	
Product/ingredient name		Result

titanium dioxide		DNEL - General pc 28 μg/m³ <u>Effects</u> : Local	opulation - Long te	rm - Inhala	tion	
		DNEL - Workers - 170 μg/m³ <u>Effects</u> : Local	Long term - Inhala	tion		
2-(2-butoxyethoxy)ethanol		DNEL - General po 6.25 mg/kg bw/day <u>Effects</u> : Systemic	opulation - Long te	rm - Oral		
		DNEL - Workers - 67.5 mg/m³ <u>Effects</u> : Local	Long term - Inhala	tion		
		DNEL - Workers - 101.2 mg/m³ <u>Effects</u> : Local	Short term - Inhala	tion		
adipohydrazide		DNEL - Workers - 17.5 mg/m³ <u>Effects</u> : Systemic	Long term - Inhala	tion		
1,2-benzisothiazol-3(2H)-one		DNEL - General po 0.345 mg/kg bw/day <u>Effects</u> : Systemic	ppulation - Long te	rm - Derma	I	
		DNEL - Workers - 0.966 mg/kg bw/day <u>Effects</u> : Systemic	-	l		
		DNEL - General po 1.2 mg/m³ <u>Effects</u> : Systemic	opulation - Long te	rm - Inhala	tion	
		DNEL - Workers - 6.81 mg/m³ <u>Effects</u> : Systemic	Long term - Inhala	tion		
PNECs Not available.						
8.2 Exposure controls						
Appropriate engineering controls	:	Good general ventilation should be suffic contaminants.	cient to control worke	er exposure	to ai	rborne
Individual protection measur	es					
Hygiene measures	:	Wash hands, forearms and face thoroug before eating, smoking and using the lav Appropriate techniques should be used t Wash contaminated clothing before reus safety showers are close to the workstati	ratory and at the end o remove potentially sing. Ensure that eye	d of the work / contamina	king p ted cl	eriod. Iothing
Eye/face protection	:	Safety eyewear complying with an appro assessment indicates this is necessary to gases or dusts. If contact is possible, the unless the assessment indicates a highe side-shields.	o avoid exposure to e following protectio	liquid splas n should be	hes, i worn	mists, ı,
Skin protection						
Hand protection	:	Chemical-resistant, impervious gloves co be worn at all times when handling chem this is necessary.				
Date of issue/Date of revision		: 22/05/2025 Date of previous issue :	No previous validation	Version	:1	9/21
AQUATOP VIRTA 38 - RAL 900	1			Label No :	1188	54

SECTION 8: Exposure controls/personal protection

•	• •	
	Recommendations : Wear suitable gloves tested to EN374.	
	> 8 hours (breakthrough time): Nitrile gloves. thickness > 0.3 mm	
	Not recommended polyvinyl alcohol (PVA) gloves	
Body protection	Personal protective equipment for the body should be selected based on the being performed and the risks involved and should be approved by a speciali before handling this product.	
Other skin protection	Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and shoul approved by a specialist before handling this product.	d be
Respiratory protection	Based on the hazard and potential for exposure, select a respirator that meet appropriate standard or certification. Respirators must be used according to respiratory protection program to ensure proper fitting, training, and other imp aspects of use.	а
	Filter type (spray application): A P	
Environmental exposure controls	Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legisla In some cases, fume scrubbers, filters or engineering modifications to the pro- equipment will be necessary to reduce emissions to acceptable levels.	

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

Appearance	
Physical state	: Liquid.
Colour	: Various
Odour	: Slight
Odour threshold	: Not available.
Melting point/freezing point	: Not available.
Initial boiling point and	:
boiling range	

	Ingredient name	°C	°F	Method
	water	100	212	
	2-(2-butoxyethoxy)ethanol	225 to 227.6	437 to 441.7	
E	lammability : Not ava	vilable		

Flammability	Not available.
Lower and upper explosion limit	: Lower: Not applicable. Upper: Not applicable.
Flash point	: Closed cup: >100°C (>212°F)
Auto-ignition temperature	1

Auto-ignition temperature

Ingredient name		°C	°F	Method
2-(2-butoxyethoxy)ethanol		210	410	DIN 51794
Decomposition temperature	: Not ava	ailable.		
рН	: 8 to 8.5	5 [Conc. (% w/w): 1	100%]	
Viscosity	: Not ava	ailable.		
Solubility(ies)	:			
Not available.				
Solubility in water	: Not ava	ailable.		
Partition coefficient: n-octanol/ water	: Not ap	plicable.		
Vapour pressure	:			

	Vapour Pressure at 20°C			V	Vapour pressure at 50°C			
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method		
water	17.5	2.3						
2-(2-butoxyethoxy)ethanol	0.022	0.0029						
Relative density	: No	t available.						
Density	: 1.2	g/cm³						
Vapour density	: No	t available.						
Particle characteristics								
Median particle size	: No	t applicable.						
0.2 Other information								
9.2.1 Information with regar	d to physi	cal hazard	classes					
Explosive properties : Not available.								
Oxidising properties : Not available.								
9.2.2 Other safety characteristics								
Not applicable.								
SECTION 10: Stabilit	y and r	eactivity	,					
I0.1 Reactivity	: No spe	cific test dat	ta related to react	ivity available fo	or this produ	ict or its ingredients		
10.2 Chemical stability	: The pr	oduct is stab	ble.					
10.3 Possibility of nazardous reactions	: Under	normal conc	litions of storage	and use, hazard	lous reactio	ons will not occur.		
10.4 Conditions to avoid	: No spe	ecific data.						
	: No spe	cific data.						
10.5 Incompatible materials								

11.1 Information on hazard classes as de	efined in Regulation (EC) No 1272/2008
Acute toxicity	
Product/ingredient name	Result
2-(2-butoxyethoxy)ethanol	Rabbit - Dermal - LD50
	2700 mg/kg
	Rat - Oral - LD50 4500 mg/kg <u>Toxic effects</u> : Behavioral - Tetany Lung, Thorax, or Respiration - Dyspnea Liver - Other changes
1,2-benzisothiazol-3(2H)-one	Rat - Oral - LD50 1020 mg/kg

Conclusion/Summary [Product] : Not available.

Acute toxicity estimates

Product/ingredient name	Oral (mg/ kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapours) (mg/l)	Inhalation (dusts and mists (mg/l)
2-(2-butoxyethoxy)ethanol 1,2-benzisothiazol-3(2H)-one	4500 450	2700 N/A	N/A N/A	N/A N/A	N/A 0.21
Skin corrosion/irritation					
Product/ingredient name	Result				
titanium dioxide	Duration o		itant (<u>posure</u> : 72 ho pplied: 300 ug		
1,2-benzisothiazol-3(2H)-one	Duration o	Skin - Mild irr f treatment/ex oncentration a	<u>posure</u> : 48 ho	ours	
Conclusion/Summary [Product] : Not a	vailable.				
Serious eye damage/eye irritation					
Product/ingredient name	Result				
2-(2-butoxyethoxy)ethanol	Rabbit - E Duration o		t e irritant p <u>osure</u> : 24 ho pplied: 20 mg		
		yes - Severe	irritant <u>pplied</u> : 20 mg		
Conclusion/Summary [Product] : Not a	vailable.				
Respiratory corrosion/irritation Not available.					
Conclusion/Summary [Product] : Not a	vailable.				
Respiratory or skin sensitization Not available.					
Skin Conclusion/Summary [Product] : Not a	vailable.				
Respiratory Conclusion/Summary [Product] : Not a	vailable.				
<mark>Germ cell mutagenicity</mark> Not available.					
Conclusion/Summary [Product] : Not a	vailable.				
Carcinogenicity It has been observed that the carcinogenic ha leading to significant impairment of particle cle Not available.				st is inhaled i	n quantities

Conclusion/Summary [Product] : Not available.

Date of issue/Date of revision	: 22/05/2025	Date of previous issue	: No previous validation	Version :1	12/21
AQUATOP VIRTA 38 - RAL 9001				Label No :11	8854

SECTION 11: Toxicological information

Reproductive toxicity

Not available.

Conclusion/Summary [Product] : Not available.

Specific target organ toxicity (single exposure) Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Not available. Information on likely routes of exposure Not available. Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Infalation : No specific data. Infalation : No specific data. Infalation : No specific data. Belayd and immediate effects as well as chronic effects from short and long-term exposure Botortial immediate is Not available. effects Potential delayed effects : Not available. Long term exposure Potential chronic health effects Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Not available. Conclusion/Summary [Product] : Not available. Not available. Conclusion/Summary [Product] : Not available. Not available. Not available. Not available. Not available. Not available. Conclusion/Summary [Product] : Not available. Secondust on ther hazards Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not known significant effects or critical hazards. Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not known significant effects or critical hazards. Not available. Conclusion/Summary [Product] : Not available. Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product]	Aspiration hazard	
Not available. Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : No specific data. Skin contact : No specific data. Delayed and immediate effects as a well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects Potential immediate : Not available. Long term exposure Potential delayed effects : Not available. Potential diaded effects : Not available. Effects Potential delayed effects : Not available. Environic health effects Rotavailable. : No known significant effects or critical hazards. Garcinogenicity : Not available. Conclusion/Summary [Product] : Not available. : Sonicant effects or critical hazards. : Sonicant effects or critical hazards. Mutagenicity : No known significant effects or critical hazard		
Not available. Potential acute health effects Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : No specific data. Skin contact : No specific data. Delayed and immediate effects as a well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects Potential immediate : Not available. Long term exposure Potential delayed effects : Not available. Potential diaded effects : Not available. Effects Potential delayed effects : Not available. Environic health effects Rotavailable. : No known significant effects or critical hazards. Garcinogenicity : Not available. Conclusion/Summary [Product] : Not available. : Sonicant effects or critical hazards. : Sonicant effects or critical hazards. Mutagenicity : No known significant effects or critical hazard		s of exposure
Potential acute health effects Eye contact I No known significant effects or critical hazards. Inhalation I No known significant effects or critical hazards. Skin contact I No known significant effects or critical hazards. Ingestion I No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact I No specific data. Inhalation I No specific data. Ingestion I No specific data. Ingestion I No specific data. Ingestion I No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate Potential immediate I Not available. effects Potential immediate Potential delayed effects I Not available. effects Not known significant effects or critical hazards. Conclusion/Summary [Product] I Not available. Conclusion/Summary [Product] I Not available. General I No known significant effects or critical hazards. Mutagenicity I No known significant effects or critical hazards. N		
Eye contact : No known significant effects or critical hazards. Inhalation : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : No specific data. Ingestion : No specific data. Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. Long term exposure Potential delayed effects : Not available. effects Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards.		ts
Inhalation : No known significant effects or critical hazards. Skin contact : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : No specific data. Inhalation : No specific data. Inhalation : No specific data. Ingestion : No specific data. Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. <th></th> <th></th>		
Skin contact : No known significant effects or critical hazards. Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalatio : No specific data. Ingestion : No specific data. Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate Potential immediate : Not available. effects : Not available. effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Reproductive toxicity : No kno		
Ingestion : No known significant effects or critical hazards. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation :: No specific data. Ingestion : No specific data. Ingestion :: No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects : Not available. effects : Not available. effects : Not available. Potential chenyel effects : Not available. effects : Not available. Potential chenyel effects : Not available. Potential chronic health effects : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Nutagenicity : No known significant effects or critical hazards. 11.21 Information on other hazards	Skin contact	-
Symptoms related to the physical, chemical and toxicological characteristics Eye contact : No specific data. Inhalation : No specific data. Skin contact :: No specific data. Ingestion :: No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Not available. : So known significant effects or critical hazards. Reproduc	Ingestion	<u> </u>
Eye contact : No specific data. Inhalation : No specific data. Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. effects Potential immediate : Not available. effects Potential delayed effects : Not available. effects Potential delayed effects : Not available. effects Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Reproduct	-	-
Inhalation:No specific data.Skin contact:No specific data.Ingestion:No specific data.Delayed and immediate effects as well as chronic effects from short and long-term exposurePotential immediate affects as well as chronic effects from short and long-term exposurePotential immediate affects:Not available.effectsPotential delayed effects:Not available.effectsPotential delayed effects:Not available.Potential delayed effects:Potential delayed effects:Not available.Potential chronic health effectsNot available.Conclusion/Summary [Product]:Not available.Carcinogenicity:No known significant effects or critical hazards.Mutagenicity:No known significant effects or critical hazards.Reproductive toxicity:No known significant effects or critical hazards.Reproductive toxicity:No known significant effects or critical hazards.Not available.Conclusion/Summary [Product]Conclusion/Summary [Product]No known significant effects or critical hazards.Not available.Conclusion/Summary [Product]Conclusion/Summary [Product]Conclusion/Summary [Product]Conclusion/Summary [Product]Conclusion/Summary [Product]Conclusion/Summary [Product]Conclusion/Summary [Product]Conclusion/Sum		
Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. effects Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No 1272/2008. 11.2.1 Endocrine disrupting properties according to the criteria set out in either Regulation (EC) No 1272/2008. No. 1907	Inhalation	
Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. effects Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information : The product does not meet the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.	Skin contact	: No specific data.
Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. effects : Not available. Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2.1 Information on other hazards : Not available. : Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information :	Ingestion	: No specific data.
Potential immediate : Not available. effects : Not available. Long term exposure : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards : No known significant effects or critical hazards. Not available. : No known significant effects or critical hazards. 11.2.1 Endocrine disrupting properties : No known significant effects or critical hazards. Not available. : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information : The product does not meet the criteria to be considered as having	Delayed and immediate eff	ects as well as chronic effects from short and long-term exposure
effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : Not known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2008 or Regulation (EC) No 1272/2008.	Short term exposure	
Long term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No. 1272/2008. 11.2.2 Other information		: Not available.
Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information	Potential delayed effects	: Not available.
effects Potential delayed effects : Not available. Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information	Long term exposure	
Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information		: Not available.
Not available. Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information		
Conclusion/Summary [Product] : Not available. General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information	Potential chronic health eff	iects
General : No known significant effects or critical hazards. Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards : No known significant effects or critical hazards. 11.2.1 Endocrine disrupting properties : Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information : Second Secon	Not available.	
Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information : Source information	Conclusion/Summary [Pr	-
Mutagenicity : No known significant effects or critical hazards. Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information	General	-
Reproductive toxicity : No known significant effects or critical hazards. 11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information	Carcinogenicity	: No known significant effects or critical hazards.
11.2 Information on other hazards 11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information	Mutagenicity	: No known significant effects or critical hazards.
11.2.1 Endocrine disrupting properties Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information	Reproductive toxicity	: No known significant effects or critical hazards.
Not available. Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.	11.2 Information on other ha	izards
 Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information 	11.2.1 Endocrine disrupting	g properties
disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. 11.2.2 Other information	Not available.	
	Conclusion/Summary [Pr	disrupting properties according to the criteria set out in either Regulation (EC)
Not available.	11.2.2 Other information	
	Not available.	

13/21

SECTION 12: Ecological information

2.1 Toxicity	
Product/ingredient name titanium dioxide	Result Acute - LC50 - Marine water Fish - Mummichog - <i>Fundulus heteroclitus</i> >1000000 μg/l [96 hours] <u>Effect</u> : Mortality Acute - LC50 - Fresh water
	Crustaceans - Water flea - <i>Ceriodaphnia dubia</i> - Neonate <u>Age</u> : <24 hours 3 mg/l [48 hours] <u>Effect</u> : Mortality
2-(2-butoxyethoxy)ethanol	Acute - LC50 - Fresh water Fish - Bluegill - <i>Lepomis macrochirus</i> <u>Size</u> : 33 to 75 mm 1300000 μg/l [96 hours] <u>Effect</u> : Mortality
1,2-benzisothiazol-3(2H)-one	Acute - LC50 - Fresh water OECD [Fish, Acute Toxicity Test] Fish - Trout - <i>Onorhynchus Mykiss</i> 1.9 mg/l [96 hours]
	Acute - EC50 OECD 202 [Daphnia sp. Acute Immobilization Test and Reproduction Test] Daphnia - Daphnia - <i>Daphnia Magna</i> 3.7 mg/l [48 hours]
	Acute - EC50 - Marine water OECD 201 [Alga, Growth Inhibition Test] Algae - Algae - <i>Skeletonema Costatum</i> 0.36 mg/l [72 hours]
	Acute - NOEC - Marine water OECD 201 [Alga, Growth Inhibition Test] Algae - Algae - <i>Skeletonema Costatum</i> 0.15 mg/l [72 hours]
Conclusion/Summary [Product] : Not a	available.
12.2 Persistence and degradability	

Product/ingredient name	Result
1,2-benzisothiazol-3(2H)-one	EU 24% [28 days]

Conclusion/Summary [Product] : Not available.

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
1,2-benzisothiazol-3(2H)-one	-	-	Inherent

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
2-(2-butoxyethoxy)ethanol	1	-	Low
1,2-benzisothiazol-3(2H)-one	-	3.2	Low

12.4 Mobility in soil Soil/water partition coefficient

: 22/05/2025 Date of previous issue

14/21

ECTION 12: Ecologi	cal inf	ormatior	ו				
Product/ingredient name		logKoc			Кос		
2-(2-butoxyethoxy)ethanol adipohydrazide 1,2-benzisothiazol-3(2H)-one	1.56 1.74 1.86		36.5981 55.2165 73.142				
Results of PMT and vPvM as	ssessme	nt			Į		
Product/ingredient name	РМТ	Р	Μ	т	vPvM	vP	vM
titanium dioxide 2-(2-butoxyethoxy)ethanol adipohydrazide 1,2-benzisothiazol-3(2H)-one Mobility Conclusion/Summary	: Not av	No No No vailable. The produc	No No No t does not n	No No No No	No No No No	No No No No	No No No PMT or vPvM.
2.5 Results of PBT and vPvE Regulation (EC) No. 1907/20 Product/ingredient name	06 [REAC	сн]					
		D	R	т	VDVR	vD	VB
-	PBT	P	B	T	vPvB	vP	vB
titanium dioxide	No	No	No	No	No	No	No
titanium dioxide 2-(2-butoxyethoxy)ethanol adipohydrazide							

Regulation (EC) No. 1272/2008 [CLP]

• • • •							
Product/ingredient name	PBT	Р	В	т	vPvB	vP	vB
titanium dioxide	No	No	No	No	No	No	No
2-(2-butoxyethoxy)ethanol	No	No	No	No	No	No	No
adipohydrazide	No	No	No	No	No	No	No
1,2-benzisothiazol-3(2H)-one	No	No	No	No	No	No	No

Conclusion/Summary Regulation (EC) No. 1272/2008 [CLP]

12.6 Endocrine disrupting properties

Not available.

Conclusion/Summary [Product]

: The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

: The product does not meet the criteria to be considered as a PBT or vPvB.

12.7 Other adverse effects

No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment meth	ods
Product	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
European waste catalogue (EWC) <u>Packaging</u>	: 080112

SECTION 13: Disposal considerations

•	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Special precautions	: This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

•						
	ADR/RID	ADN	IMDG	ΙΑΤΑ		
14.1 UN number or ID number	Not regulated.	Not regulated.	Not regulated.	Not regulated.		
14.2 UN proper shipping name	-	-	-	-		
14.3 Transport hazard class(es)	-	-	-	-		
14.4 Packing group	-	-	-	-		
14.5 Environmental hazards	No.	No.	No.	No.		

user

- 14.6 Special precautions for : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.
- 14.7 Maritime transport in bulk according to IMO instruments

: Not relevant/applicable due to nature of the product.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

÷

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Product/ingredient name	%	Designation [Usage]
2-(2-butoxyethoxy)ethanol	≤3	55 [Consumer paint]

Labelling

Other EU regulations			
Industrial emissions (integrated pollution prevention and control) - Air	:	Not listed	
Industrial emissions (integrated pollution prevention and control) - Water	:	Not listed	
Date of issue/Date of revision		: 22/05/2025	

: 22/05/2025 Date of previous issue

AQUATOP VIRTA 38 - RAL 9001

: No previous validation

Explosive precursors	: Not applicat	le.		
Ozone depleting substance	es (EU 2024/59	<u>0)</u>		
Not listed.				
Prior Informed Consent (Pl	<u>C) (649/2012/E</u>	<u>U)</u>		
Not listed.				
Persistent Organic Pollutan Not listed.	<u>its</u>			
Seveso Directive				
This product is not controlled	under the Seve	so Directive.		
lational regulations				
<u>Austria</u>	De masitte el			
Limitation of the use of organic solvents	: Permitted.			
Belgium				
Book VI carcinogenic agent	ts annex VI.2-1	- VI.2-3		
Ingredient name				Status
Silice				Listed
Noirs de charbon				Listed
Czech Republic				
Storage code	: IV			
<u>Denmark</u> Fire class	: IV-1			
Executive Order No. 1795/2				
	015		Annex I Section A	Annex I Section B
Ingredient name titanium dioxide			Listed	Annex i Section E
			LISIEU	-
MAL-code Protection based on MAL	: 1-1	to the regulations on wo	rk involving ooded n	raduata tha fallowi
FIOLECTION DASED ON MAL	-	apply to the use of pers	• •	•
	coveralls/pro clothes do n shield must case, other In all sprayir	General: Gloves must be worn for all work that may result in soiling. Apron/ overalls/protective clothing must be worn when soiling is so great that regular w lothes do not adequately protect skin against contact with the product. A face hield must be worn in work involving spattering if a full mask is not required. In t ase, other recommended use of eye protection is not required.		
		nd arm protectors/apron/co or as instructed.	overalls/protective cloth	ning must be worn as
MAL-code: 1-1 Application: During downtimes, cleaning and repair in closed facilitien booths or cabins, if there is a risk of contact with wet paint or organic				
	- Air-supplied half mask must be worn.			
When spraying in existing* spray booths, if the operator is outside				itside the spray zone.
	- Air-supplied half-mask and arm protectors must be worn.			
		atomising spraying in exist pray-booth type where the		

AQUATOP VIRTA 38 - RAL 9001	
AGOATOL VINTA 30 - INAE 3001	

SECTION 15: Regulatory information

		g where atomisation occurs in cabins or spray booths where the the spray zone and during spraying outside a closed facility, cabin
	-supplied half r	mask, eye protection, coveralls and hood must be worn.
	trolleys, etc, m	drying/drying ovens that are temporarily placed on such things as must be equipped with a mechanical exhaust system to prevent ems from passing through workers' inhalation zone.
		polishing treated surfaces, a mask with dust filter must be worn. inding, eye protection must be worn. Work gloves must always be
	tion The regu	ulations contain other stipulations in addition to the above.
	e Regulations.	
Low-boiling liquids	product contai uld be air-fed.	ains low-boiling point liquids. Any respiratory protective equipment
Restrictions on use		professional users below 18 years of age. See the National nent Authorities Executive Order regarding Young People At Work.
List of undesirable substances	listed	
Carcinogenic waste		must be labeled: Contains a substance or substances regulated genvironment legislation on cancer risks.
<u>Finland</u> France		
Social Security Code, Articles L 461-1 to L 461-7	-butoxyethoxy)	ethanol RG 84
Reinforced medical surveillance		77 determining the list of activities which require reinforced ce: not applicable
<u>Germany</u>		
Storage class (TRGS 510)		
Hazardous incident ordina		
This product is not controlled	the Germany H	Hazardous Incident Ordinance.
Hazard class for water		

Technical instruction on air quality control (TA Luft)

Number [Class]	Description	%
5.2.1 5.2.4 [III] 5.2.5 5.2.5 [I]	Total dust Gaseous inorganic substances Organic substances Organic substances	18 0.059 28.6 2
ΑΟΧ	: The product contains organically bound halogens and can contribute to value in waste water.	the AOX
Italy		
D.Lgs. 152/06	: Not determined.	
Netherlands		
Water Discharge Policy (ABM)	(3) Hazardous for aquatic organisms, may have long-term hazardous effects in quatic environment. Decontamination effort: A	
<u>Norway</u>		
<u>Sweden</u>		
Switzerland		
VOC content	: Exempt.	

Date of issue/Date of revision AQUATOP VIRTA 38 - RAL 9001 : 22/05/2025 Date of previous issue

: No previous validation Version : 1

SECTION 15: Regulatory information

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

15.2 Chemical safety assessment

: This product contains substances for which Chemical Safety Assessments are still required.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms	: ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]
	DMEL = Derived Minimal Effect Level
	DNEL = Derived No Effect Level
	EUH statement = CLP-specific Hazard statement
	N/A = Not available
	PBT = Persistent, Bioaccumulative and Toxic
	PNEC = Predicted No Effect Concentration
	RRN = REACH Registration Number
	SGG = Segregation Group
	vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

Full text of abbreviated H statements

H302	Harmful if swallowed.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H319	Causes serious eye irritation.
H330	Fatal if inhaled.
H351	Suspected of causing cancer.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H411	Toxic to aquatic life with long lasting effects.

Full text of classifications [CLP/GHS]

ACUTE TOXICITY - Category 2
ACUTE TOXICITY - Category 4
SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1
LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1
LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2
CARCINOGENICITY - Category 2
SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1
SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
SKIN CORROSION/IRRITATION - Category 2
SKIN SENSITISATION - Category 1
SKIN SENSITISATION - Category 1A

SECTION 16: Other information			
Date of issue/ Date of revision	: 22/05/2025		
Date of previous issue	: No previous validation		
Version	: 1 AQUATOP VIRTA 38_RAL 9001	RAL 9001	

Notice to reader

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Date of issue/Date of revision AQUATOP VIRTA 38 - RAL 9001